Tower Research Capital LLC TRC Has $637,000 Stock Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Tower Research Capital LLC TRC grew its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 275.9% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 19,965 shares of the company’s stock after buying an additional 14,654 shares during the period. Tower Research Capital LLC TRC’s holdings in Apellis Pharmaceuticals were worth $637,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. National Bank of Canada FI grew its stake in Apellis Pharmaceuticals by 266,361.5% in the fourth quarter. National Bank of Canada FI now owns 1,385,600 shares of the company’s stock valued at $44,214,000 after acquiring an additional 1,385,080 shares during the period. Cibc World Markets Corp bought a new stake in Apellis Pharmaceuticals during the 4th quarter worth approximately $41,014,000. Norges Bank acquired a new stake in Apellis Pharmaceuticals during the 4th quarter worth approximately $34,662,000. Jennison Associates LLC lifted its stake in Apellis Pharmaceuticals by 51.6% in the fourth quarter. Jennison Associates LLC now owns 2,760,404 shares of the company’s stock valued at $88,084,000 after buying an additional 939,289 shares in the last quarter. Finally, Natixis acquired a new position in shares of Apellis Pharmaceuticals in the fourth quarter valued at approximately $27,782,000. Institutional investors own 96.29% of the company’s stock.

Insider Activity at Apellis Pharmaceuticals

In related news, CEO Cedric Francois sold 2,824 shares of the company’s stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $29.52, for a total value of $83,364.48. Following the transaction, the chief executive officer now owns 415,695 shares in the company, valued at approximately $12,271,316.40. This represents a 0.67 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, General Counsel David O. Watson sold 5,569 shares of the company’s stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $25.10, for a total transaction of $139,781.90. Following the completion of the transaction, the general counsel now owns 138,730 shares in the company, valued at approximately $3,482,123. This trade represents a 3.86 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 11,005 shares of company stock worth $299,037. Insiders own 6.80% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently commented on APLS shares. The Goldman Sachs Group dropped their price objective on shares of Apellis Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating on the stock in a report on Monday, March 3rd. HC Wainwright reaffirmed a “buy” rating and issued a $57.00 price objective on shares of Apellis Pharmaceuticals in a research report on Monday, March 3rd. Scotiabank boosted their price objective on shares of Apellis Pharmaceuticals from $30.00 to $31.00 and gave the company a “sector perform” rating in a research report on Wednesday, April 2nd. Wedbush cut their price objective on shares of Apellis Pharmaceuticals from $30.00 to $29.00 and set a “neutral” rating on the stock in a research report on Monday, March 3rd. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Apellis Pharmaceuticals from $50.00 to $54.00 and gave the company an “overweight” rating in a research report on Tuesday, March 4th. Eight research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $45.35.

Apellis Pharmaceuticals Stock Down 0.3 %

Apellis Pharmaceuticals stock opened at $17.49 on Monday. The firm has a market capitalization of $2.20 billion, a PE ratio of -8.62 and a beta of 0.85. The company’s 50-day moving average is $22.70 and its 200-day moving average is $27.66. Apellis Pharmaceuticals, Inc. has a fifty-two week low of $16.98 and a fifty-two week high of $49.38. The company has a debt-to-equity ratio of 1.91, a current ratio of 4.36 and a quick ratio of 3.73.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its quarterly earnings data on Friday, February 28th. The company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.08. The company had revenue of $212.50 million for the quarter, compared to analyst estimates of $197.92 million. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. Apellis Pharmaceuticals’s revenue for the quarter was up 45.2% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.73) EPS. Sell-side analysts anticipate that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Apellis Pharmaceuticals Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).